Join

Compare · BCTX vs NVS

BCTX vs NVS

Side-by-side comparison of BriaCell Therapeutics Corp. (BCTX) and Novartis AG (NVS): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both BCTX and NVS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • NVS is the larger of the two at $286.95B, about 8760.5x BCTX ($32.8M).
  • BCTX has hit the wire 1 time in the past 4 weeks while NVS has been quiet.
  • NVS has more recent analyst coverage (25 ratings vs 1 for BCTX).
MetricBCTXNVS
Company
BriaCell Therapeutics Corp.
Novartis AG
Price
-
-
Market cap
$32.8M
$286.95B
1M return
-
-
1Y return
-
-
Sector
Health Care
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NASDAQ
NYSE
IPO
News (4w)
1
0
Recent ratings
1
25
BCTX

BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.

NVS

Novartis AG

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Latest BCTX

Latest NVS